{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-130966","form_type":"8-K","ticker":"CTSO","cik":"0001175151","company_name":"Cytosorbents Corp","filed_at":"2022-12-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.825236+00:00","generated_at":"2026-06-20T21:47:42.377526+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"CytoSorbents draws $5M debt from Bridge Bank, extends $10M drawdown to March 2023","bullets":["Received $5M non-dilutive term loan; no financial covenants on initial tranche.","Drawdown period for remaining $10M extended from Dec 31, 2022 to March 1, 2023.","Loan at Index Rate +1.25% (min 3.25%), capped at 8%; interest-only until Jan 2024, principal+interest to Dec 2025.","Funds to support U.S. STAR-T pivotal trial for DrugSorb-ATR™, commercial growth, and cost control."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-130966","json":"https://secwatch.observer/filing/0001104659-22-130966.json","markdown":"https://secwatch.observer/filing/0001104659-22-130966.md","text":"https://secwatch.observer/filing/0001104659-22-130966.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1175151/000110465922130966/0001104659-22-130966-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1175151/000110465922130966/tm2233609d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T21:47:42.377526+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"00ae122aa19bcc62ba20ca255f5ae4d9e9b6f9ed","claim":"Cytosorbents Corp amended Fifth Amendment with Bridge Bank valued at $10 million (effective 2022-12-28).","evidence_excerpt":"On December 28, 2022 (the “ Fifth Amendment Date ”), CytoSorbents Corporation, a Delaware corporation (the “ Company ”), CytoSorbents Medical, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“ CytoSorbents Medical ” and, together with the Company, the “ Borrower ”) and Bridge Bank, a division of Western Alliance Bank, an Arizona corporation (the “ Bank ”), entered into an amendment (the “ Fifth Amendment ”) to that certain Amended and Restated Loan and Security Agreement","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465922130966/0001104659-22-130966-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Bridge Bank"},{"label":"Value","value":"$10 million"},{"label":"Effective","value":"2022-12-28"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}